Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dendrimer porphyrin micelle (DP/M) is an experimental nanomedicine formulation designed for photodynamic therapy (PDT) and photodynamic diagnosis (PDD). It consists of a third-generation aryl ether dendrimer porphyrin with a zinc core encapsulated within a polymeric micelle, typically composed of poly(ethylene glycol)-poly(L-lysine) or poly(aspartic acid) block copolymers. This micellar structure facilitates the selective accumulation of the photosensitizer in tumor tissues and neovascularized areas via the enhanced permeability and retention (EPR) effect. Upon activation by specific wavelengths of light (e.g., 635 nm), the dendrimer porphyrin generates reactive oxygen species (ROS) to induce localized cytotoxicity while minimizing dark toxicity. The formulation also exhibits intense fluorescence, allowing for simultaneous lesion detection and treatment. It has been investigated primarily by researchers at the University of Tokyo for indications such as esophageal cancer, lung carcinoma, and corneal neovascularization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dendrimer porphyrin micelle.